Medicaid Gets Higher Rebates For Brand Drugs Compared To Medicare Part D, OIG Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Findings could carry extra significance as congressional "super committee" looks for ways to cut at least $1.2 trillion in federal spending.
You may also be interested in...
OIG Urges Look At Additional Part D Rebates
Congress and CMS should “explore the costs and benefits” of additional Part D rebates, HHS Inspector General says after finding that rebates for selected brands were “substantially higher” for Medicaid than Medicare. But with GOP-controlled Congress, chances of passing mandatory rebates are slim.
OIG Raises Reimbursement Policy Questions For Avastin And Lucentis In Wake Of CATT Findings
Analysis of money spent on the treatments for wet age-related macular degeneration offers an argument for least costly alternative policy as a way of cutting health care spending.
OIG Raises Reimbursement Policy Questions For Avastin And Lucentis In Wake Of CATT Findings
Analysis of money spent on the treatments for wet age-related macular degeneration offers an argument for least costly alternative policy as a way of cutting health care spending.